Rho kinase inhibitors for glaucoma treatment - Review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos brasileiros de oftalmologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600388 |
Resumo: | ABSTRACT Glaucoma is a progressive optic neuropathy characterized by the loss of ganglion cells and their axons. A major risk factor for glaucomatous visual field loss is elevated intraocular pressure (IOP), and several studies have shown that lowering IOP reduces the risk of glaucomatous progression. Currently, an increasing number of researches involve Rho kinase inhibitors, which are a new pharmacological class of hypotensive agents specifically targeting the diseased trabecular outflow pathway. Rho kinase inhibitors reduce IOP by increasing aqueous humor drainage through the primary outflow pathway in the eye, which is known as the trabecular meshwork. In addition to improving the outflow facility of the trabecular meshwork, Rho kinase inhibitors also enhance retinal ganglion cell survival after ischemic injury and increase ocular blood flow. |
id |
CBO-2_339175d76d60d999f7eb2eaddf16bc83 |
---|---|
oai_identifier_str |
oai:scielo:S0004-27492015000600388 |
network_acronym_str |
CBO-2 |
network_name_str |
Arquivos brasileiros de oftalmologia (Online) |
repository_id_str |
|
spelling |
Rho kinase inhibitors for glaucoma treatment - ReviewGlaucomaIntraocular pressureRho-associated kinasesAqueous humorTrabecular meshworkABSTRACT Glaucoma is a progressive optic neuropathy characterized by the loss of ganglion cells and their axons. A major risk factor for glaucomatous visual field loss is elevated intraocular pressure (IOP), and several studies have shown that lowering IOP reduces the risk of glaucomatous progression. Currently, an increasing number of researches involve Rho kinase inhibitors, which are a new pharmacological class of hypotensive agents specifically targeting the diseased trabecular outflow pathway. Rho kinase inhibitors reduce IOP by increasing aqueous humor drainage through the primary outflow pathway in the eye, which is known as the trabecular meshwork. In addition to improving the outflow facility of the trabecular meshwork, Rho kinase inhibitors also enhance retinal ganglion cell survival after ischemic injury and increase ocular blood flow.Conselho Brasileiro de Oftalmologia2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600388Arquivos Brasileiros de Oftalmologia v.78 n.6 2015reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20150103info:eu-repo/semantics/openAccessGermano,Renato Antunes SchiaveFinzi,SimoneChalla,PratapSusanna Junior,Remoeng2015-12-09T00:00:00Zoai:scielo:S0004-27492015000600388Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2015-12-09T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false |
dc.title.none.fl_str_mv |
Rho kinase inhibitors for glaucoma treatment - Review |
title |
Rho kinase inhibitors for glaucoma treatment - Review |
spellingShingle |
Rho kinase inhibitors for glaucoma treatment - Review Germano,Renato Antunes Schiave Glaucoma Intraocular pressure Rho-associated kinases Aqueous humor Trabecular meshwork |
title_short |
Rho kinase inhibitors for glaucoma treatment - Review |
title_full |
Rho kinase inhibitors for glaucoma treatment - Review |
title_fullStr |
Rho kinase inhibitors for glaucoma treatment - Review |
title_full_unstemmed |
Rho kinase inhibitors for glaucoma treatment - Review |
title_sort |
Rho kinase inhibitors for glaucoma treatment - Review |
author |
Germano,Renato Antunes Schiave |
author_facet |
Germano,Renato Antunes Schiave Finzi,Simone Challa,Pratap Susanna Junior,Remo |
author_role |
author |
author2 |
Finzi,Simone Challa,Pratap Susanna Junior,Remo |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Germano,Renato Antunes Schiave Finzi,Simone Challa,Pratap Susanna Junior,Remo |
dc.subject.por.fl_str_mv |
Glaucoma Intraocular pressure Rho-associated kinases Aqueous humor Trabecular meshwork |
topic |
Glaucoma Intraocular pressure Rho-associated kinases Aqueous humor Trabecular meshwork |
description |
ABSTRACT Glaucoma is a progressive optic neuropathy characterized by the loss of ganglion cells and their axons. A major risk factor for glaucomatous visual field loss is elevated intraocular pressure (IOP), and several studies have shown that lowering IOP reduces the risk of glaucomatous progression. Currently, an increasing number of researches involve Rho kinase inhibitors, which are a new pharmacological class of hypotensive agents specifically targeting the diseased trabecular outflow pathway. Rho kinase inhibitors reduce IOP by increasing aqueous humor drainage through the primary outflow pathway in the eye, which is known as the trabecular meshwork. In addition to improving the outflow facility of the trabecular meshwork, Rho kinase inhibitors also enhance retinal ganglion cell survival after ischemic injury and increase ocular blood flow. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600388 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000600388 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/0004-2749.20150103 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Oftalmologia v.78 n.6 2015 reponame:Arquivos brasileiros de oftalmologia (Online) instname:Conselho Brasileiro de Oftalmologia (CBO) instacron:CBO |
instname_str |
Conselho Brasileiro de Oftalmologia (CBO) |
instacron_str |
CBO |
institution |
CBO |
reponame_str |
Arquivos brasileiros de oftalmologia (Online) |
collection |
Arquivos brasileiros de oftalmologia (Online) |
repository.name.fl_str_mv |
Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO) |
repository.mail.fl_str_mv |
aboonline@cbo.com.br||abo@cbo.com.br |
_version_ |
1754209028665245696 |